Tryp Therapeutics
Tryp is leading the next wave of psychedelic drug development.
Tryp is leading the next wave of psychedelic drug development.
Tryp Therapeutics is a pioneering biotechnology startup with the slogan "Tryp is leading the next wave of psychedelic drug development." The company is focused on developing novel formulations for the administration of psilocin in combination with psychotherapy to address diseases with unmet medical needs. Their lead program, TRP-8803, a proprietary formulation of IV-infused psilocin, aims to alleviate the limitations of oral psilocybin. Tryp has ongoing Phase 2a clinical trials for the treatment of Binge Eating Disorder at the University of Florida and upcoming trials for the treatment of fibromyalgia at the University of Michigan, both exhibiting potential in utilizing TRP-8802. The company, founded in 2019 and based in the United States, received a $6.50M Post-IPO Equity investment on 01 May 2024. The potential of TRP-8803 to enhance efficacy, safety, and patient experience indicates promising future prospects in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $6.50M | - | 01 May 2024 | |
| Post-IPO Debt | $3.22M | 1 | Jason Carroll | 02 Nov 2023 |
| Post-IPO Debt | $2.40M | - | 12 Apr 2023 | |
| Post-IPO Equity | $6.00M | - | 04 Feb 2022 | |
| Post-IPO Equity | $2.00M | 1 | Marc Lustig | 05 Feb 2021 |
No recent news or press coverage available for Tryp Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.